NK cells have been seen as potential agents in adoptive immunotherapy for cancer. The main challenge for the success of this approach is to obtain a great quantity of activated NK cells for adoptive transfer. The present study had aimed to evaluate the effect of a feeder layer of irradiated MSCs in the in vitro expansion of NK cells. MSCs were obtained from the bone marrow (BM) cells remaining in the bag and filter used in the transplantation of hematopoietic stem cells. NK cells were obtained from peripheral blood (PB) of healthy volunteers. NK expansion and activation were stimulated by culture with artificial antigen-presenting cells (aAPCs) and IL-2, in the presence or absence of BM-MSCs. NK cell proliferation, phenotypic expression and cytotoxic activity were evaluated. Both culture conditions showed high NK purity with predominance of NK CD56brightCD16+ subset post expansion. However, cultures without the presence of MSCs showed higher NK proliferation, expression of activation markers (CD16 and NKG2D) and related cytotoxic activity. In this experimental study, the presence of a feeder layer of irradiated BM-MSCs interfered negatively in the expansion of PB-NKs, limiting their growth and activation. Further investigation is needed to understand the mechanisms of NK-MSC interaction and its implications.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
The datasets supporting the conclusions of this article are included within the article.
Killer cell immunoglobulin-like receptor
Human leukocyte antigen class I
Antibody-dependent cellular cytotoxicity
Graft versus leukemia
Graft versus host disease
Hematopoietic stem cell transplantation
White blood cells
Artificial antigen-presenting cells
Mesenchymal stem cells
Fetal bovine serum
Peripheral blood mononuclear cells
- CD3dep PB-MNCs:
Median fluorescence intensity
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008). Functions of natural killer cells. Nature Immunology,9, 503–510.
Luci, C., & Tomasello, E. (2008). Natural killer cells: Detectors of stress. International Journal of Biochemistry & Cell Biology,40, 2335–2340.
Campbell, K. S., & Hasegawa, J. (2013). Natural killer cell biology: An update and future directions. The Journal of Allergy and Clinical Immunology,132, 536–544.
Parodi, M., Meazza, R., Vitale, C., Pietra, G., Carrega, P., & Vitale, M. (2019). Isolation, expansion, and characterization of natural killer cells and their precursors as a tool to study cancer immunosurveillance. Methods in Molecular Biology, 1884, 87–117.
Yoon, S. R., Kim, T. D., & Choi, I. (2015). Understanding of molecular mechanisms in natural killer cell therapy. Experimental & Molecular Medicine,47, e141.
Granzin, M., Wagner, J., Köhl, U., Cerwenka, A., Huppert, V., & Ullrich, E. (2017). Shaping of natural killer cell antitumor activity by ex vivo cultivation. Frontiers in Immunology,8, 458.
Baggio, L., Laureano, Á., Silla, L. M. D. R., & Lee, D. A. (2017). Natural killer cell adoptive immunotherapy: Coming of age. Clinical Immunology,177, 3–11.
Ferreira-Teixeira, M., Paiva-Oliveira, D., Parada, B., Alves, V., Sousa, V., Chijioke, O., et al. (2016). Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells. BMC Medicine,14, 163.
Shevtsov, M., & Multhoff, G. (2016). Immunological and translational aspects of NK cell-based antitumor immunotherapies. Frontiers in Immunology,7, 492.
Moretta, L., Pietra, G., Montaldo, E., Vacca, P., Pende, D., Falco, M., et al. (2014). Human NK cells: From surface receptors to the therapy of leukemias and solid tumors. Frontiers in Immunology,5, 87.
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., et al. (2012). Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE,7, e30264.
Liu, Y., Wu, H. W., Sheard, M. A., Sposto, R., Somanchi, S. S., Cooper, L. J., et al. (2013). Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clinical Cancer Research,19, 2132–2143.
Horwitz, E. M., Le Blanc, K., Dominici, M., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., et al. (2005). Therapy ISfC: Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy,7, 393–395.
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy,8, 315–317.
Ullah, I., Subbarao, R. B., & Rho, G. J. (2015). Human mesenchymal stem cells—current trends and future prospective. Bioscience Reports. https://doi.org/10.1042/BSR20150025.
Thomas, H., Jäger, M., Mauel, K., Brandau, S., Lask, S., & Flohé, S. B. (2014). Interaction with mesenchymal stem cells provokes natural killer cells for enhanced IL-12/IL-18-induced interferon-gamma secretion. Mediators of Inflammation,2014, 143463.
Nauta, A. J., & Fibbe, W. E. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood,110, 3499–3506.
Najar, M., Raicevic, G., Crompot, E., Fayyad-Kazan, H., Bron, D., Toungouz, M., et al. (2016). The immunomodulatory potential of mesenchymal stromal cells: A story of a regulatory network. Journal of Immunotherapy,39, 45–59.
Cui, R., Rekasi, H., Hepner-Schefczyk, M., Fessmann, K., Petri, R. M., Bruderek, K., et al. (2016). Human mesenchymal stromal/stem cells acquire immunostimulatory capacity upon cross-talk with natural killer cells and might improve the NK cell function of immunocompromised patients. Stem Cell Research & Therapy,7, 88.
Zhao, K., & Liu, Q. (2016). The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation. Journal of Hematology & Oncology,9, 46.
Chatterjee, D., Marquardt, N., Tufa, D. M., Beauclair, G., Low, H. Z., Hatlapatka, T., et al. (2014). Role of gamma-secretase in human umbilical-cord derived mesenchymal stem cell mediated suppression of NK cell cytotoxicity. Cell Communication and Signaling,12, 63.
Choi, I., Yoon, S. R., Park, S. Y., Kim, H., Jung, S. J., Jang, Y. J., et al. (2014). Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: A dose-escalation study. Biology of Blood and Marrow Transplantation,20, 696–704.
Spaggiari, G. M., Capobianco, A., Becchetti, S., Mingari, M. C., & Moretta, L. (2006). Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood,107, 1484–1490.
Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N., & Papamichail, M. (2006). Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells,24, 74–85.
Spaggiari, G. M., Capobianco, A., Abdelrazik, H., Becchetti, F., Mingari, M. C., & Moretta, L. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood,111, 1327–1333.
Aggarwal, S., & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood,105, 1815–1822.
Boissel, L., Tuncer, H. H., Betancur, M., Wolfberg, A., & Klingemann, H. (2008). Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biology of Blood and Marrow Transplantation,14, 1031–1038.
Rasmusson, I., Ringdén, O., Sundberg, B., & Le Blanc, K. (2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation,76, 1208–1213.
Friedman, R., Betancur, M., Boissel, L., Tuncer, H., Cetrulo, C., & Klingemann, H. (2007). Umbilical cord mesenchymal stem cells: Adjuvants for human cell transplantation. Biology of Blood and Marrow Transplantation,13, 1477–1486.
Smyth, M. J., Hayakawa, Y., Takeda, K., & Yagita, H. (2002). New aspects of natural-killer-cell surveillance and therapy of cancer. Nature Reviews Cancer,2, 850–861.
Takahashi, E., Kuranaga, N., Satoh, K., Habu, Y., Shinomiya, N., Asano, T., et al. (2007). Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells. Scandinavian Journal of Immunology,65, 126–138.
Baume, D. M., Robertson, M. J., Levine, H., Manley, T. J., Schow, P. W., & Ritz, J. (1992). Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. European Journal of Immunology,22, 1–6.
The authors thank the volunteers for their donation of blood.
This work was financially supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Financiadora de Estudos e Projetos (Finep) and Fundo de Incentivo à Pesquisa e Eventos do Hospital de Clínicas de Porto Alegre (FIPE-HCPA).
Conflict of interest
The authors declare that they have no competing interests.
Informed consent was obtained from all volunteers. The study was performed according to the declaration of Helsinki and was approved by the Research Ethics Committee of Hospital de Clínicas de Porto Alegre.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Pedroso, J.F., de Souza Valim, V., Pezzi, A. et al. An Experimental Study Comparing the Expansion of Peripheral Blood Natural Killer (NK) Cells Cultured with Artificial Antigen-Presenting Cells, in the Presence or Absence of Bone Marrow Mesenchymal Stem Cells (MSCs). Mol Biotechnol 62, 306–315 (2020). https://doi.org/10.1007/s12033-020-00250-2